NCT02471430View on ClinicalTrials.gov

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2022

Study Completion Date

December 31, 2023

Conditions
HIV Infection
Interventions
DRUG

Panobinostat

Panobinostat will be administered orally.

DRUG

Pegylated Interferon-alpha2a

Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.

Trial Locations (1)

02114

Massachusetts General Hospital CRS (MGH CRS), Boston

Sponsors

Collaborators (2)

Novartis
Genentech, Inc.
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER